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Hypereosinophilia  (HE)  is  deﬁned  as  peripheral  blood
eosinophils  >1.5  eosinophils  ×  109/L  blood  on  2  examinations
and/or  tissue  HE  deﬁned  by  the  following:  (1)  the  percent-
age  of  eosinophils  in  the  bone  marrow  section  exceeds  20%
of  all  nucleated  cells  and/or  (2)  the  pathologist  is  of  the
opinion  that  tissue  inﬁltration  by  eosinophils  is  extensive
and/or  (3)  marked  deposition  of  eosinophil  granule  proteins
is  found  (in  the  absence  or  presence  of  major  tissue  inﬁl-
tration  by  eosinophils).  Hypereosinophilic  syndrome  (HES)
is  deﬁned  by  the  following:  (1)  criteria  for  peripheral  blood
hypereosiniphilia  (HE)  fulﬁlled  and  (2)  organ  damage  and/or
dysfunction  attributable  to  tissue  HE  and  (3)  exclusion  of
other  disorders  or  conditions  as  major  reason  for  organ  dam-
age.  HES  subtypes  have  been  deﬁned;  these  include  (1)
idiopathic  HES,  (2)  primary  (neoplastic)  HES,  (3)  secondary
(reactive)  HES.1 We  here  report  a  case  of  idiopathic  hyper-
eosinophilic  syndrome  successfully  treated  with  imatinib.
A  forty-six-year-old  male  patient  was  admitted  to  our
clinic  with  complaints  of  itching,  cough,  shortness  of  breath,
and  stomach  pain.  The  symptoms  had  increased  over  the
last  six  months.  He  had  a  history  of  chronic  smoking
(30  pack-years).  There  was  no  history  of  any  drug  use.
Admission  blood  pressure:  110/80  mmHg;  respiratory  rate
20/min;  pulse  95/min;  saturation  in  room  air  was  found  to
be  95%.  Breath  sounds  were  bilaterally  decreased.  Widely
excoriated  itchy  lesions  were  present.  There  was  tender-
ness  in  the  epigastric  region.  Blood  eosinophil  rate  was
55.4%  (9880/mm3).  Parasite  stool  examination  and  sero-
logic  tests  were  negative.  A  mild  obstructive  pattern  was
present  in  the  pulmonary  function  test.  However,  the
patient  did  not  beneﬁt  from  treatment  with  high  doses
of  inhaled  corticosteroids/2  agonists.  Laboratory  tests
showed  no  signiﬁcant  alterations  except  increased  vitamin
B12:  1081  pg/ml  (reference  range:  111--663  pg/ml)  and  total
IgE:  194  IU/ml  (reference  range:  <100  IU/ml)  autoimmunity









tCentrilobular  ground-glass  nodules  were  found  to  be
ore  prominent  in  the  upper  lobes  of  the  lungs  in
horax  computed  tomography  (CT)  (Fig.  1a).  Abdomi-
al  CT  and  ultrasonography  were  found  to  be  normal.
ndoscopic  biopsy  for  stomach  pain  was  reported  as
osinophilic  gastritis.  Eosinophilic  inﬁltration  was  observed
n  transbronchial  lung  biopsy.  Numerous  eosinophilic  gran-
locytes  (40%)  were  observed  in  bone  marrow  biopsy
ithout  increased  blast  cells.  A  prominent  mast  cell
opulation  was  not  observed.  There  was  no  malignant
nﬁltration.  FIPLI-PDGFR mutation,  JAK-2  mutation  and
hiladelphia  chromosome  were  also  found  to  be  nega-
ive.
In  our  case,  differential  diagnosis  was  performed  for  pri-
ary  (hematopoietic  neoplasms  with  HE)  and  secondary
ES,  (helminth  infections,  allergic  reactions,  atopic  dis-
ases,  drug  reactions  (allergic  or  toxic),  Hodgkin  disease,  B-
r  T-cell  lymphoma/leukemia,  Langerhans  cell  histiocytosis,
ndolent  systemic  mastocytosis,  solid  tumors/malignancy,
llergic  bronchopulmonary  aspergillosis,  chronic  inﬂam-
atory  disorders,  autoimmune  diseases  and  lymphoid
ariant  of  HES),  organ-restricted  conditions  accompanied
y  HE  (eosinophilic  gastrointestinal  disorders,  eosinophilic
neumonia,  dermatologic  diseases,  etc.)  and  speciﬁc
yndromes  accompanied  by  HE  (Gleich  syndrome,  Churg-
trauss  syndrome,  eosinophilia  myalgia  syndrome,  Hyper-IgE
yndrome).1--6 The  patient  was  diagnosed  with  idiopatic  HES
fter  exclusion  of  all  primary  and  secondary  causes  and
xclusion  of  other  conditions  and  syndromes.  The  patient
as  started  on  imatinib  mesylate  therapy  with  400  mg/day
ecause  he  did  not  respond  to  corticosteroids  (CS)  and
ydroxyurea  therapy.  The  treatment  was  reduced  to  a
00  mg  in  the  third  month  of  treatment  due  to  normalization
f  eosinophil  levels  and  disappearance  of  all  complaints.  The
round-glass  nodules  disappeared  after  1  year  of  imatinib
reatment  (Fig.  1b).
CS  have  been  used  for  decades  in  the  treatment  of  HES,
ith  the  exception  of  PDGFR-  associated  HES.  A  number
f  cytotoxic  therapies  have  been  used  for  the  management
f  corticosteroid-refractory  HES.  Of  these,  hydroxyurea  has
een  the  most  extensively  studied.  However,  the  utility  of
ydroxyurea  monotherapy  is  limited  in  the  treatment  of
ES.  Imatinib  mesylate  is  a tyrosine  kinase  inhibitor  with
ctivity  against  several  receptor  tyrosine  kinases,  including
he  fusion  kinase  FIP1L1/PDGFR-,  which  is  responsi-
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Figure  1a  Axial  CT  image  at  lung  window  setting  showing
centrilobular  ground-glass  nodules  (circles).
Figure  1b  Axial  CT  image  at  the  same  level  as  in  Fig.  1a









should  be  reserved  for  corticosteroid  nonresponders  cases
with  idiopatic  HES.
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